Abstract

Cancer cells develop multiple strategies to evade T cell-mediated killing. On one hand, cancer cells may preferentially rely on certain amino acids for rapid growth and metastasis. On the other hand, sufficient nutrient availability and uptake are necessary for mounting an effective T cell anti-tumor response in the tumor microenvironment (TME). Here we demonstrate that tumor cells outcompete T cells for cystine uptake due to high Slc7a11 expression. This competition induces T-cell exhaustion and ferroptosis, characterized by diminished memory formation and cytokine secretion, increased PD-1 and TIM-3 expression, as well as intracellular oxidative stress and lipid-peroxide accumulation. Importantly, either Slc7a11 deletion in tumor cells or intratumoral cystine supplementation improves T cell anti-tumor immunity. Mechanistically, cystine deprivation in T cells disrupts glutathione synthesis, but promotes CD36 mediated lipid uptake due to dysregulated cystine/glutamate exchange. Moreover, enforced expression of glutamate-cysteine ligase catalytic subunit (Gclc) promotes glutathione synthesis and prevents CD36 upregulation, thus boosting T cell anti-tumor immunity. Our findings reveal cystine as an intracellular metabolic checkpoint that orchestrates T-cell survival and differentiation, and highlight Gclc as a potential therapeutic target for enhancing T cell anti-tumor function.

Details

Title
Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8+ T cells
Author
Han, Chenfeng 1 ; Ge, Minmin 1 ; Xing, Pengfei 2 ; Xia, Tian 3 ; Zhang, Cangang 4   VIAFID ORCID Logo  ; Ma, Kaili 1 ; Ma, Yifu 2 ; Li, Shicheng 5 ; Li, Wenhui 1 ; Liu, Xiaowei 1 ; Zhang, Baojun 4 ; Zhang, Liyuan 2   VIAFID ORCID Logo  ; Zhang, Lianjun 1   VIAFID ORCID Logo 

 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839) 
 The Second Affiliated Hospital of Soochow University, Department of Radiotherapy & Oncology, Suzhou, China (GRID:grid.452666.5) (ISNI:0000 0004 1762 8363); The Second Affiliated Hospital of Soochow University, Center for Cancer Diagnosis and Treatment, Suzhou, China (GRID:grid.452666.5) (ISNI:0000 0004 1762 8363); The Second Affiliated Hospital of Soochow University, Laboratory for Combined Radiotherapy and Immunotherapy of Cancer, Suzhou, China (GRID:grid.452666.5) (ISNI:0000 0004 1762 8363) 
 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Soochow University, Institute of Biology and Medical Sciences (IBMS), Suzhou, China (GRID:grid.263761.7) (ISNI:0000 0001 0198 0694) 
 Xi’an Jiaotong University, Department of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243); Xi’an Jiaotong University Health Science Center, Institute of Infection and Immunity, Translational Medicine Institute, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243); Xi’an Jiaotong University, Key Laboratory of Environment and Genes Related to Diseases, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243); Xi’an Key Laboratory of Immune Related Diseases, Xi’an, China (GRID:grid.43169.39) 
 The Second Affiliated Hospital of Soochow University, Center for Cancer Diagnosis and Treatment, Suzhou, China (GRID:grid.452666.5) (ISNI:0000 0004 1762 8363) 
Pages
145
Publication year
2024
Publication date
Feb 2024
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2927020739
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.